https://pressroom.prlog.org/ArkBio/ Shanghai Ark Biopharmaceutical Co., Ltd. Latest Press Releases https://www.prlog.org/13138306-arkbio-completed-dosing-of-first-cohort-in-australian-phase-trial-of-adfc-drug-ak0406.html Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the first cohort of healthy volunteers has been dosed in a phase I clinical trial of AK0406, a novel long-acting antiviral drug-Fc conjugate (ADFC) drug for influenza infection,...Fri, 10 Apr 2026 01:00:00 GMT https://www.prlog.org/13126974-novel-anti-fibrotic-drug-ak3280-cleared-by-fda-to-initiate-phase-2-poc-clinical-trial-in-ipf.html Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that FDA has cleared its Investigational New Drug (IND) application for AK3280, a novel anti-fibrotic therapy for the treatment of idiopathic pulmonary fibrosis (IPF).Thu, 12 Feb 2026 04:00:00 GMT https://www.prlog.org/13107677-arkbio-initiates-phase-2-clinical-trial-of-ak0610a-preventive-monoclonal-antibody-for-rsv-infection.html Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the initiation of a Phase II clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infection.Thu, 30 Oct 2025 01:00:00 GMT https://www.prlog.org/13087608-arkbio-ziresovir-included-into-pediatric-rsv-drug-priority-list-by-who.html In the newly released "Paediatric drug optimization for respiratory syncytial virus (PADO-RSV) meeting report" by Global Accelerator for Paediatric formulations (GAP-f), the World Health Organization (WHO) host network, ziresovir (10mg) has been included.Wed, 16 Jul 2025 01:00:00 GMT https://www.prlog.org/13082315-arkbios-new-drug-application-for-adhd-therapeutic-azstarys-accepted-and-granted-priority-review-by-china-nmpa.html Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the National Medical Products Administration (NMPA) has officially accepted its New Drug Application (NDA) for Azstarys (serdexmethylphenidate/dexmethylphenidate extended-release...Mon, 16 Jun 2025 01:00:00 GMT https://www.prlog.org/13079368-arkbio-and-partex-deepen-strategic-collaboration-to-advance-novel-atr-inhibitor-ak0658.html Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), a leading Chinese biopharmaceutical company, today announced an expanded strategic collaboration with Partex, a leader in AI-driven pharmaceutical innovation, to jointly develop and out-license AK0658,.Fri, 30 May 2025 01:00:00 GMT https://www.prlog.org/13076895-arkbio-announces-positive-phase-ii-results-of-ak3280-for-treatment-of-idiopathic-pulmonary-fibrosis.html Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of idiopathic pulmonary fibrosis (IPF).Fri, 16 May 2025 01:00:00 GMT https://www.prlog.org/13071445-the-lancet-child-adolescent-health-publishes-phase-iii-trial-24m-follow-up-results-of-ziresovir.html The Lancet Child & Adolescent Health , a leading international journal in pediatric and adolescent medicine, has published the Phase III clinical trial results of ziresovir, a novel RSV-targeted antiviral drug developed by Shanghai Ark...Wed, 16 Apr 2025 01:00:00 GMT https://www.prlog.org/13067701-arkbio-announces-the-completion-of-phase-iii-study-for-ak0901-in-the-treatment-of-adhd-in-china.html Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the successful completion of the Phase III clinical study of AK0901, a novel drug for the treatment of attention deficit hyperactivity disorder (ADHD).Mon, 24 Mar 2025 01:00:00 GMT https://www.prlog.org/13054202-shanghai-arkbio-announces-strategic-collaboration-with-partex-for-partnership-and-out-licensing.html Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), a clinical-stage, privately held biopharmaceutical company, today announced a strategic collaboration with Partex, a leader in AI-driven pharmaceutical innovation.Fri, 27 Dec 2024 00:18:00 GMT